Kintara Therapeutics (FRA:3DMA) Pre-Tax Income : €-7.72 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Kintara Therapeutics's pretax income for the three months ended in Jun. 2024 was €-2.16 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was €-7.72 Mil. Kintara Therapeutics's pretax margin was %.

Kintara Therapeutics Pre-Tax Income Historical Data

The historical data trend for Kintara Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Pre-Tax Income Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Pre-Tax Income

Get a 7-Day Free Trial

-8.10

-31.79

-21.44

-13.52

-7.73

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Pre-Tax Income	Get a 7-Day Free Trial															-3.08	-2.78	-0.94	-1.85	-2.16

Competitive Comparison of Kintara Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Kintara Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Pre-Tax Income falls into.

Kintara Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Kintara Therapeutics's Pretax Income for the fiscal year that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-7.851	+	-0.007	+	0	+	0	+	0.129
	=	-7.73

Kintara Therapeutics's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.216	+	0	+	0	+	0	+	0.057
	=	-2.16

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.72 Mil.

Kintara Therapeutics (FRA:3DMA) Pre-Tax Income Explanation

Kintara Therapeutics's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.159	/	0
	=	%

Kintara Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (FRA:3DMA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines